Sistema de Salut de Catalunya
[Guerra I] Gastroenterology Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain. [Bujanda L] Gastroenterology Unit, Hospital Donostia/Instituto Biodonostia, Universidad del País Vasco, Donostia-San Sebastián, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain. [Mañosa M] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain. Gastroenterology Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Pérez-Martínez I] Gastroenterology Unit, Hospital Universitario Central de Asturias, and Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain. [Casanova MJ] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain. Gastroenterology Unit, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain. [de la Peña L] Gastroenterology Unit, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, Universitat de Barcelona, l'Hospitalet de Llobregat, Spain. [Piqueras M] Unitat de Gastroenterologia, Hospital de Terrassa, Consorci Sanitari Terrassa, Terrassa, Spain
Consorci Sanitari de Terrassa
2023-08-14T11:44:49Z
2023-08-14T11:44:49Z
2023-01-25
Inflammatory bowel disease; Lymphoma; Thiopurines
Enfermedad inflamatoria intestinal; Linfoma; Tiopurinas
Malaltia inflamatòria de l'intestí; Limfoma; Tiopurines
An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 ± 17 years old) and anti-TNF drugs (47 ± 17) than in those patients not treated with these drugs (63 ± 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies.
Article
Published version
English
Intestins - Inflamació; Limfomes; Factor de necrosi tumoral; DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases; DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Monokines::Tumor Necrosis Factor-alpha; ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::monocinas::factor de necrosis tumoral alfa
MDPI
Cancers;15(3)
https://doi.org/10.3390/cancers15030750
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
